The global market for non-opioid pain patches is experiencing significant growth, with sales surpassing USD 3.3 billion in 2022 and projected to reach an impressive USD 4.4 billion by 2029. This surge is underpinned by a Compound Annual Growth Rate (CAGR) of 4.1% over the forecast period, driven by a growing demand for safer, non-narcotic alternatives to pain management.
The increasing prevalence of chronic pain worldwide is a major factor fueling this market expansion. Pain, which affects more people than diabetes, cancer, and cardiovascular diseases combined, represents a serious global health burden. As such, the demand for effective pain management solutions is on the rise, with non-opioid pain patches emerging as a critical tool in addressing this widespread issue.
Chronic pain, resulting from various conditions such as arthritis, spine disease, pancreatitis, and physical injuries, has become a pervasive concern across all demographics. As the incidence of these conditions continues to rise, the need for alternative, non-opioid pain relief solutions has gained momentum. Non-opioid pain patches, in particular, offer an attractive option for patients seeking effective relief without the risks associated with opioid medications.
One of the key factors propelling the growth of the non-opioid pain patches market is their ability to significantly reduce the risk of addiction compared to opioid-based treatments, such as fentanyl patches. This characteristic is especially vital in the context of the ongoing opioid crisis, as healthcare providers and patients increasingly turn to safer, non-addictive options for managing chronic pain.
Additionally, the growing preference for minimally invasive pain management solutions is expected to further drive market growth. Non-opioid pain patches offer a convenient and less invasive alternative to traditional pain relief methods, making them increasingly popular among both healthcare providers and patients.
As the global demand for non-addictive, effective pain relief solutions continues to rise, the non-opioid pain patches market is poised for sustained growth. This upward trend presents significant opportunities for industry players to innovate and expand within this rapidly growing market, addressing the critical need for safer pain management practices worldwide.
Key Takeaways of Non-opioids Pain Patches Market Study:
- In terms of product type, the lidocaine patches segment is expected to capture over 65% of revenue share in the non-opioid pain patches market.
- Owing to superior topical effectiveness with minimal side-effects and prolonged transdermal drug release, lidocaine patches are the most preferred product type.
- In terms of distribution channel, hospital pharmacies and retail pharmacies & drug stores are expected to collectively hold over 70% of total value in the non-opioid pain patches market during the forecast period.
- North America is the highest revenue generating market by region, due to high R&D projects and conducive regulatory environment for non-opioid pain therapeutics. Europe is expected to offer lucrative opportunities, owing to the large aging population and increasing per capital healthcare expenditure.
High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report!
Competition Landscape:
The predominant focus among key players in the global market for non-opioid pain patches revolves around developing topical patches devoid of addictive properties, catering to both chronic and acute pain relief needs. Efforts are directed towards improving skin adhesion and prolonging analgesic effects through innovative therapeutic alternatives. Additionally, select players are deeply invested in collaborative research endeavors with academic institutions to introduce fresh non-narcotic pain patch solutions.
For instance,
- In January 2021, a team of researchers led by Duke University unveiled a groundbreaking surgical patch designed to release non-opioid pain relievers directly to wound sites, providing sustained relief over several days before naturally dissolving. This innovative polymer patch administers a controlled dose of a medication capable of inhibiting the COX-2 enzyme, known for driving inflammation and pain.
- In July 2020, the U.S. Food and Drug Administration (FDA) granted approval for an 8% capsaicin patch targeted at alleviating neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. This non-opioid, topical treatment represents a unique solution, delivering prescription-strength capsaicin directly to the skin without systemic effects, marking a significant advancement in pain management options.
Top of Form
Key Companies Profiled:
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Hisamitsu Pharmaceutical Co., Inc.
- Clarion Brands
- Endo Pharmaceuticals
- TEH SENG Pharmaceutical
- Veridian Healthcare
- Sorrento Therapeutics (SCILEX Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Teikoku Seiyaku Co. Ltd.
Non-opioid Pain Patches Market by Category:
Product Type:
- Lidocaine Patches
- Diclofenac Patches
- Methyl Salicylate Patches
- Capsaicin Patches
- Ketoprofen Patches
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube